What risk of death would people take to be cured of HIV and why? A survey of people living with HIV

[1]  G. Salkeld.  Valuing health for regulatory cost-effectiveness analysis , 2007 .

[2]  Lisa M. Schwartz,et al.  Assessing Values for Health: Numeracy Matters , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  Andrew N. Phillips,et al.  Projected life expectancy of people with HIV according to timing of diagnosis , 2012, AIDS.

[4]  Á. Borges.  Combination antiretroviral therapy and cancer risk , 2017, Current opinion in HIV and AIDS.

[5]  B. Rimer,et al.  Longitudinal Predictors of Nonadherence to Maintenance of Mammography , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[6]  A. Abernethy,et al.  Do patient attributes predict oncologist empathic responses and patient perceptions of empathy? , 2010, Supportive Care in Cancer.

[7]  Richard D Moore,et al.  Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Nachega,et al.  HIV-Related Stigma, Isolation, Discrimination, and Serostatus Disclosure , 2012, Journal of the International Association of Physicians in AIDS Care.

[9]  Rashmi Rodrigues,et al.  ‘What Do I Know? Should I Participate?’ Considerations on Participation in HIV Related Research among HIV Infected Adults in Bangalore, South India , 2013, PloS one.

[10]  S. Lewin,et al.  The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.

[11]  B. Gazzard,et al.  Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study , 2007, The Lancet.

[12]  C. Grady,et al.  Exploring Decision‐Making of HIV‐Infected Hispanics and African Americans Participating in Clinical Trials , 2011, The Journal of the Association of Nurses in AIDS Care : JANAC.

[13]  D. Defreitas.  Race and HIV clinical trial participation. , 2010, Journal of the National Medical Association.

[14]  Jianqing Xu,et al.  Willingness to Participate in HIV Therapeutic Vaccine Trials among HIV-Infected Patients on ART in China , 2014, PloS one.

[15]  C. Tremblay,et al.  Altruism motivates participation in a therapeutic HIV vaccine trial (CTN 173) , 2010, AIDS care.

[16]  J. Neumann,et al.  Theory of games and economic behavior , 1945, 100 Years of Math Milestones.

[17]  B. Hanusa,et al.  HIV-Infected African Americans are Willing to Participate in HIV Treatment Trials , 2007, Journal of General Internal Medicine.

[18]  S. Bellino,et al.  Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein , 2011, AIDS care.

[19]  Peter Reiss,et al.  Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals , 2010, AIDS.

[20]  A Gafni,et al.  The standard gamble method: what is being measured and how it is interpreted. , 1994, Health services research.

[21]  R. Paredes,et al.  Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population , 2013, AIDS.

[22]  M. Finkelstein,et al.  Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds , 2006, AIDS care.

[23]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[24]  L A Lenert,et al.  Effects on Preferences of Violations of Procedural Invariance , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  Michael P. Arnold,et al.  Recruitment and ethical considerations in HIV cure trials requiring treatment interruption , 2015, Journal of virus eradication.

[26]  D. Klein,et al.  Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals , 2016, Journal of acquired immune deficiency syndromes.

[27]  M A Hlatky,et al.  Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. , 1992, JAMA.

[28]  A. Skinner,et al.  Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US , 2017, Journal of virus eradication.

[29]  Lonny Reisman,et al.  Full coverage for preventive medications after myocardial infarction. , 2011, The New England journal of medicine.

[30]  G W Torrance,et al.  Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.

[31]  G. Poole,et al.  Motivators to Participation in Actual HIV Vaccine Trials , 2014, AIDS and Behavior.

[32]  K. Ethier,et al.  Recruitment in AIDS Clinical Trials: Investigation of Sociodemographic and Psychosocial Factors Affecting Participation in Clinical Research , 1999, AIDS and Behavior.

[33]  K. Sikkema,et al.  Internalized Stigma Among People Living with HIV-AIDS , 2002, AIDS and Behavior.

[34]  J. Fox,et al.  A global survey of HIV‐positive people's attitudes towards cure research , 2017, HIV medicine.

[35]  G. Dowsett,et al.  HIV cure research: a survey of Australian people living with HIV on perspectives, perceived benefits and willingness to participate in trials , 2016 .